ASCO: Adding Olaparib Slows High-Risk Early Breast Cancer
Higher rates of invasive disease-free survival seen in adjuvant setting for HER2-negative early-stage disease with germline BRCA1 or BRCA2 mutations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.